AstraZeneca | AZN

Stock Price
12,007.00
Daily Change
-19.00 -0.16%
Monthly
11.78%
Yearly
1.79%
Q2 Forecast
10,495.41
Peers Price Chg Day Year Date
ABBV AbbVie 167.20 -0.81 -0.48% 3.34% Apr/25
ALC Alcon AG 71.62 0.06 0.08% 12.54% Apr/26
ALM Almirall 8.53 0.07 0.77% -7.63% Apr/26
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
ARGX argenx SE 344.60 -1.60 -0.46% 0.53% Apr/26
AZN AstraZeneca 12,007.00 -19.00 -0.16% 1.79% Apr/26
BAYN Bayer 27.41 0.52 1.91% -54.10% Apr/26
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
FME Fresenius Medical Care 37.96 0.17 0.44% -10.86% Apr/26
FRE Fresenius 27.03 -0.15 -0.55% 3.96% Apr/26
GEN Genmab 1,961.00 45.50 2.38% -29.26% Apr/26
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GLPG Galapagos 26.60 0.04 0.15% -24.22% Apr/26
GRF GRIFOLS 8.32 0.23 2.87% -8.17% Apr/26
GSK GlaxoSmithKline 1,639.00 -1.50 -0.09% 14.06% Apr/26
HIK Hikma Pharmaceutical 1,901.00 47.00 2.54% 7.40% Apr/26
HLN Haleon 331.30 -0.20 -0.06% -5.67% Apr/26
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
LONN Lonza 523.40 9.60 1.87% -4.77% Apr/26
MRK Merck 151.80 1.70 1.13% -5.36% Apr/26
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
NOVN Novartis 89.48 -0.52 -0.58% -2.05% Apr/26
ORNBV Orion 35.86 0.40 1.13% -17.70% Apr/26
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PHIA Philips 19.39 0.13 0.65% 1.19% Apr/26
REC Recordati 49.00 0.20 0.41% 18.62% Apr/26
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
ROG Roche Holding 219.50 0.70 0.32% -20.53% Apr/26
SAN Sanofi 90.12 -1.51 -1.64% -11.50% Apr/26
UCB UCB 123.05 -2.05 -1.64% 43.85% Apr/26

Indexes Price Day Year Date
UKX GB100 8120 40.84 0.51% 3.68% Apr/26

AstraZeneca traded at 12,016.00 this Friday April 26th, decreasing 10.00 or 0.08 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 11.86 percent. Over the last 12 months, its price rose by 1.87 percent. Looking ahead, we forecast AstraZeneca to be priced at 10,495.41 by the end of this quarter and at 9,966.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.